Posted inCardiology news
Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks
Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.
Posted inClinical Updates news OB/GYN & Women's Health
Elinzanetant: A Novel Non-Hormonal Neurokinin 1 and 3 Receptor Antagonist Transforming Menopausal Vasomotor Symptom Management
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2b/3 trials with added benefits on sleep and quality of life.
Posted innews OB/GYN & Women's Health
Elinzanetant for Menopausal Hot Flashes: A 52‑Week Phase 3 Trial Shows Modest, Durable Benefit and Acceptable Safety Profile
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean difference of −1.6 vs placebo (P < .001); numerical advantages persisted through 50–52 weeks with no signal for hepatotoxicity or endometrial hyperplasia.
Posted inOB/GYN & Women's Health
FDA Approves Bayer’s Lynkuet (Elinzanetant): A Novel Dual Neurokinin Receptor Antagonist for Menopausal Hot Flashes
Bayer's Lynkuet (elinzanetant), a first-in-class dual neurokinin 1 and 3 receptor antagonist, has received FDA approval for treatment of moderate to severe menopausal vasomotor symptoms, demonstrating sustained efficacy and favorable safety in phase 3 trials.
Menopause and Multiple Sclerosis: Evaluating the Impact on Disability Progression
A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging's role in disease trajectory.
Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review
This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.
Estradiol Hormone Therapy Route Influences Memory Types in Postmenopausal Women
Estradiol-based hormone therapy's impact on memory varies by administration route—with transdermal delivery linked to better episodic memory and oral delivery to improved prospective memory. Earlier menopause onset correlates with poorer cognitive performance.
Posted inOB/GYN & Women's Health Specialties
Unraveling Menopause: Symptom Prevalence and Severity Across the Transition—Insights from the Australian Women’s Midlife Years (AMY) Study
The AMY Study highlights vasomotor symptoms, particularly hot flushes, as key indicators of perimenopause onset, challenging traditional cycle-based definitions and underscoring the need for tailored symptom management across diverse reproductive stages.
Posted inAI news OB/GYN & Women's Health Specialties
Evaluating Digital Therapeutics for Midlife Women’s Menopausal Symptoms: A Synthesis of Recent Randomized Controlled Trials
This review synthesizes evidence on mobile digital therapeutics targeting vasomotor and behavioral health symptoms in menopausal and midlife women, highlighting efficacy, engagement, and implications for scalable symptom management.
Long-Term Fracture Risk After Menopausal Hormone Therapy: New Insights from a Landmark Study
Large-scale UK data reveal a transient increase but sustained long-term reduction in fracture risk after discontinuing menopausal HRT, challenging prior assumptions and guiding future clinical decisions.
Posted innews OB/GYN & Women's Health Specialties
Rethinking Menopausal Hormone Therapy: Experts Urge FDA to Revise Outdated Warnings
Leading experts call on the FDA to update boxed warnings on menopausal hormone therapies, arguing current labels are outdated and deter women from effective, safe treatments.
Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy
A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.
Posted innews OB/GYN & Women's Health Specialties
FDA Extends Review of Bayer’s Elinzanetant for Menopause Symptoms
The FDA delays its review of Bayer's elinzanetant, a novel treatment for menopause-related vasomotor symptoms, by 90 days, citing the need for additional data assessment.